SEER, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
SEER, INC. (SEER) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $86.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-11
- SEER, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $18.33M, a 59.57% decline year-over-year.
- SEER, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $68.26M, a 22.10% decline year-over-year.
- SEER, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $40.63M, a 40.84% decline year-over-year.
- SEER, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $64.22M, a 19.04% decline year-over-year.
- SEER, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $237.81M, a 30.47% decline from fiscal 2024.
- SEER, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $342.02M, a 23.19% decline from fiscal 2023.
- SEER, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $445.31M, a 75.57% increase from fiscal 2022.
- SEER, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $253.65M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $86.59M 10-Q · filed 2026-08-11 | $127.22M derived: sum of 3 quarters · filed 2026-08-11 | $191.44M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $68.26M 10-Q · filed 2026-05-13 | $108.89M derived: sum of 2 quarters · filed 2026-05-13 | $173.11M derived: sum of 3 quarters · filed 2026-05-13 | $218.44M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $40.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $104.85M derived: sum of 2 quarters · filed 2026-03-02 | $150.19M derived: sum of 3 quarters · filed 2026-08-11 | $237.81M 10-K · filed 2026-03-02 |
| 2025-09-30 | $64.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $109.56M derived: sum of 2 quarters · filed 2026-08-11 | $197.18M 10-Q · filed 2025-11-06 | $265.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $45.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $132.96M 10-Q · filed 2026-08-11 | $201.64M derived: sum of 3 quarters · filed 2026-08-11 | $280.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $87.63M 10-Q · filed 2026-05-13 | $156.31M derived: sum of 2 quarters · filed 2026-05-13 | $235.63M derived: sum of 3 quarters · filed 2026-05-13 | $295.25M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $68.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $148.00M derived: sum of 2 quarters · filed 2026-03-02 | $207.62M derived: sum of 3 quarters · filed 2026-03-02 | $342.02M 10-K · filed 2026-03-02 |
| 2024-09-30 | $79.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $138.94M derived: sum of 2 quarters · filed 2025-11-06 | $273.35M 10-Q · filed 2025-11-06 | $366.34M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $59.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $194.03M 10-Q · filed 2025-08-06 | $287.02M derived: sum of 3 quarters · filed 2025-08-06 | $333.77M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $134.41M 10-Q · filed 2025-05-13 | $227.40M derived: sum of 2 quarters · filed 2025-05-13 | $274.15M derived: sum of 3 quarters · filed 2025-05-13 | $433.59M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $92.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $139.75M derived: sum of 2 quarters · filed 2025-03-03 | $299.19M derived: sum of 3 quarters · filed 2025-03-03 | $445.31M 10-K · filed 2025-03-03 |
| 2023-09-30 | $46.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $206.19M derived: sum of 2 quarters · filed 2024-11-06 | $352.32M 10-Q · filed 2024-11-06 | $518.10M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $159.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $305.57M 10-Q · filed 2024-08-08 | $471.35M derived: sum of 3 quarters · filed 2024-08-08 | $535.21M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $146.13M 10-Q · filed 2024-05-08 | $311.91M derived: sum of 2 quarters · filed 2024-05-08 | $375.77M derived: sum of 3 quarters · filed 2024-05-08 | $387.77M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $165.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | $229.65M derived: sum of 2 quarters · filed 2024-03-04 | $241.65M derived: sum of 3 quarters · filed 2024-03-04 | $253.65M 10-K · filed 2024-03-04 |
| 2022-09-30 | $63.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $75.86M derived: sum of 2 quarters · filed 2023-11-07 | $87.86M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $24.00M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $12.00M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |